Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be able to access treatment with Alnylam's gene-silencing drug Amvuttra. The ruling by reimbursement ...
The European Commission has approved BridgeBio's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market clash with Pfizer. The oral drug ...
The outlook for transthyretin amyloidosis (ATTR amyloidosis) depends on factors such as your type, affected organs, and how early you start treatment. Average survival rates differ by type: familial ...
Amvuttra (vutrisiran) is a prescription drug that’s used to treat nerve damage and weakened heart muscles related to a condition called ATTR amyloidosis. It’s given as an injection under your skin by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results